Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in primary IgA nephropathy
NCT05799287Phase 3Active, not recruiting
- Sponsor
- RemeGen
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in IgA nephropathy (IgAN), sponsored by RemeGen. Started Apr 2023; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05799287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799287.